Neo-PATH: TAHP for patients with HER2-positive breast cancer

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Mahtani & Dr. SchwartzbergПодробнее

Study of Neratinib for Patients with HER2-Positive Breast Cancer with Brain MetastasesПодробнее

Highlights from ESMO: DESTINY-Breast03Подробнее

Neoadjuvant Treatment Strategies for HER2-Positive Breast CancerПодробнее

Dr. Yardley on the RESPECT Trial in HER2-Positive Breast CancerПодробнее

CompassHER2-pCR: de-escalation of neoadjuvant chemotherapy for breast cancerПодробнее

Impact of Recent Data on Guidelines for Management of HER2-positive Breast CancerПодробнее

Overview of Neoadjuvant Therapy in HER2+ Breast CancerПодробнее

Dual HER2 blockade in patients with HER2-positive breast cancer after pCRПодробнее

Dr. Tripathy on Neoadjuvant Treatment Strategies in HER2+ Breast CancerПодробнее

Updates in treatments for HER2-positive GEAПодробнее

Dr. Pegram on Challenges in Neoadjuvant Treatment for HER2-Positive Breast CancerПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Traina & Dr. CareyПодробнее

Study of Immunotherapy Combinations for Patients with HER2-Positive Metastatic Breast CancerПодробнее

Reducing Risk in Residual Breast CancerПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Bagegni & Dr. GradisharПодробнее

Dr. Sanft on Treatment Options in HER2-Positive Breast CancerПодробнее

Key challenge associated with the management of HR+/HER2- breast cancerПодробнее

Neoadjuvant therapy with neratinib plus trastuzumab in locally advanced HER2-positive breast cancerПодробнее